Greenwich LifeSciences (Greenwich LifeSciences) Forward PE Ratio : 0.00 (As of May. 24, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Greenwich LifeSciences Forward PE Ratio?

Greenwich LifeSciences's Forward PE Ratio for today is 0.00.

Greenwich LifeSciences's PE Ratio without NRI for today is 0.00.

Greenwich LifeSciences's PE Ratio for today is 0.00.

Greenwich LifeSciences Forward PE Ratio Historical Data

The historical data trend for Greenwich LifeSciences's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Greenwich LifeSciences Forward PE Ratio Chart

Greenwich LifeSciences Annual Data

Trend

Forward PE Ratio

Greenwich LifeSciences Quarterly Data

Forward PE Ratio

Competitive Comparison of Greenwich LifeSciences's Forward PE Ratio

For the Biotechnology subindustry, Greenwich LifeSciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Greenwich LifeSciences's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Greenwich LifeSciences's Forward PE Ratio falls into.

Greenwich LifeSciences Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Greenwich LifeSciences (NAS:GLSI) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Greenwich LifeSciences Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Greenwich LifeSciences's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Greenwich LifeSciences (Greenwich LifeSciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Greenwich LifeSciences Inc (NAS:GLSI) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477

Website

https://www.greenwichlifesciences.com

Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells in order to inhibit the spread of cancer.

Executives

Snehal Patel	director, officer: CHIEF EXECUTIVE OFFICER	2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Jaye Thompson	officer: VPC AND REGULATORY AFFAIRS	2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380
Frank Joseph Daugherty	director, officer: CHIEF MEDICAL OFFICER	2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Kenneth Hallock	director	2311 SPARTAN TRAIL, SUGAR LAND TX 77479
David Mcwilliams	director	2575 WEST BELLFORT STREET, HOUSTON TX 77054-9816
Eric Rothe	director	2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Kinnary Patel	10 percent owner	3992 BLUEBONNET DR., BUILDING 14, STAFFORD TX 77477
Panjaj Amrit Patel	10 percent owner	50726 LAKESIDE DRIVE, GRANGER IN 46530